Skip to main content
Equibles
ALLO logo

ALLO · Allogene Therapeutics, Inc. · Documents

Track ALLO — free

Use ALLO with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ALLO.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.84 +0.01 (+1.41%) At close · Nov 13 Play latest call Q2 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$290.58M
Shares
346.47M
Volume · Nov 13 11.66M Avg daily vol (3M) 7.37M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $0 10-K filed Mar 12, 2026 Quarterly report FY2026 Q3 Revenue $0 10-Q filed Nov 6, 2026 Latest results Financial results 8-K filed Nov 5, 2026 Earnings call Q2 2026 earnings call Held Aug 12, 2026
2026
Nov 6
Quarterly report 10-Q FY2026 Q3, ended Sep 30
ALPHA3 interim data favored cema-cel over observation

Allogene Therapeutics reported ALPHA3 interim results showing MRD negativity in 58.3% (7/12) of cema-cel patients versus 16.7% (2/12) under observation, with no treatment-related serious adverse events reported in the cema-cel arm.

Revenue $0 Net loss $50.37M Diluted EPS -$0.15
Read from the MD&A section
4 source passages
Unless the context requires otherwise, references to the “Company”, “Allogene,” “we,” “us” and “our” refer to Allogene Therapeutics, Inc. On April 13, 2026, we announced results from the planned interim futility analysis of the first 24 randomized patients to the two ongoing arms in ALPHA3. At the protocol-defined data cutoff, which was triggered when the 24th patient completed Day 45 MRD assessment, MRD negativity was observed in 58.3% (7/12) of patients in the cema-cel arm compared with 16.7% (2/12) of patients in the observation arm, and at the Day 45 post-randomization MRD assessment, ctDNA levels decreased from baseline by a median of 97.7% in the cema-cel arm compared with a median increase of 26.6% in the observation arm. In the cema-cel arm, no treatment-related serious adverse events, cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, graft-versus-host disease or treatment-related hospitalizations were reported, and ten of the twelve treated patients were managed in the outpatient setting post-infusion. Open the document at this passage
Aug 12
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $4.64M Net loss $42.68M Diluted EPS -$0.13
Apr 30
Proxy statement DEF 14A Meeting Jun 18, 2026
Proxy statement AI summary on its way
Apr 15
Current report 8-K Events of Apr 14
Other events AI summary on its way
Apr 13
Current report 8-K
Other events AI summary on its way
Apr 13
Current report 8-K
Other events AI summary on its way
Mar 12
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $0 Net loss $190.89M Diluted EPS -$0.87
2025
Mar 13
Annual report 10-K FY2024, ended Dec 31
Annual report for FY2024
Revenue $22K ▼ 76.8% Net loss $257.59M Diluted EPS -$1.32
2024
Showing 1–50 of 161 documents
Key facts CIK 1737287 CUSIP 019770106 13F (30d) 158 filings 136 filers Visit website Investor relations